Status:
COMPLETED
Stage III NSCLC RWE in Chinese Patients
Lead Sponsor:
AstraZeneca
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-130 years
Brief Summary
The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) ...
Eligibility Criteria
Inclusion
- Male or female aged 18 years or older.
- Provision of informed consent prior to any study specific procedures.
- Histologically or cytologically confirmed locally advanced, stage III NSCLC (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology).
Exclusion
- Enrolment in studies that prohibit any participation in this observational study.
- Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown.
- Prior surgery, radiotherapy or systemic therapy for NSCLC, including chemotherapy, targeted therapy, anti-angiogenesis, etc.
Key Trial Info
Start Date :
July 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 29 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04023812
Start Date
July 16 2019
End Date
February 29 2024
Last Update
February 18 2025
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, China, China, 100020
2
Research Site
Beijing, China, China, 100044
3
Research Site
Beijing, China, China
4
Research Site
Datong, China, China, 030000